Influence of ethnicity on IGF‐I and procollagen III peptide (P‐III‐P) in elite athletes and its effect on the ability to detect GH abuse

Erotokritou‐Mulligan, Ioulietta; Bassett, E. Eryl; Cowan, David; Bartlett, Christiaan; McHugh, Cathy; Sönksen, Peter H.; Holt, Richard

doi:10.1111/j.1365-2265.2008.03319.x

Cited by 45 publications

(34 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P3NP levels rise after a bone fracture or soft tissue muscle injury (9,(33)(34)(35). P3NP response to rhGH administration may be affected by the age, gender, and stage of pubertal maturation, whereas ethnicity has only a small effect (6,17,36). Our data show that P3NP also increased after testosterone administration in men who did not receive rhGH; thus, the P3NP response is not unique to rhGH.…”

Section: Discussionsupporting

confidence: 49%

See 1 more Smart Citation

N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone

Meikle¹

2010

Yearbook of Endocrinology

View full text Add to dashboard Cite

Context:Biomarkers that predict musculoskeletal response to anabolic therapies should expedite drug development. During collagen synthesis in soft lean tissue, N-terminal propeptide of type III procollagen (P3NP) is released into circulation. We investigated P3NP as a biomarker of lean body mass (LBM) and muscle strength gains in response to testosterone and GH.Design: Community-dwelling older men received GnRH agonist plus 5 or 10 g testosterone gel plus 0, 3, or 5 g recombinant human GH daily. P3NP levels were measured at baseline and wk 4, 8, 12, and 16.LBMandappendicularskeletalmusclemass(ASM)weremeasuredbydual-energyx-rayabsorptiometry. Results:One hundred twelve men completed treatment; 106 underwent serum P3NP measurements. P3NP levels were higher at wk 4 than baseline (6.61 Ϯ 2.14 vs. 4.51 Ϯ 1.05, P Ͻ 0.0001) and reached plateau by wk 4 in men receiving testosterone alone. However, wk 8 P3NP levels were higher than wk 4 levels in men receiving testosterone plus recombinant human GH. Increases in P3NP from baseline to wk 4 and 16 were significantly associated with gains in LBM (r ϭ 0.26, P ϭ 0.007; r ϭ 0.53, P Ͻ 0.001) and ASM (r ϭ 0.17, P ϭ 0.07; r ϭ 0.40, P Ͻ 0.0001). Importantly, for participants receiving only testosterone, P3NP increases at wk 4 and 16 were related to muscle strength gains (r ϭ 0.20, P ϭ 0.056 and r ϭ 0.36, P ϭ 0.04). In stepwise regression, change in P3NP explained 28 and 30% of the change in ASM and LBM, respectively, whereas change in testosterone but not IGF-I and age provided only small improvements in the models. Conclusion:Early changes in serum P3NP levels are associated with subsequent changes in LBM and ASM during testosterone and GH administration. Serum P3NP may be a useful early predictive biomarker of anabolic response to GH and testosterone. The past decade has witnessed substantial pharmaceutical and academic investment in the development of function promoting anabolic therapies that improve physical function and health-related outcomes (1). The leading function promoting anabolic molecules that are under development, androgens, myostatin inhibitors, and GH, are potential promyogenic agents that are expected to improve physical function primarily by increasing skeletal muscle mass. Considering the enormous resources required for conducting large efficacy trials, serum biomar-

show abstract

Section: Discussionsupporting

confidence: 49%

“…P3NP has been explored as a marker of GH doping in athletes (6,10,12,13,15,17) and shown to respond to exercise (11) and testosterone (10). In previous studies, administration of supraphysiological doses of rhGH has been associated with significant elevations of P3NP levels (10), which persisted for 8 wk after GH discontinuation (12).…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone

Meikle¹

2010

Yearbook of Endocrinology

View full text Add to dashboard Cite

show abstract

“…(mg/l) post-GH Delta maximal change in IGFI from baseline P-III-P (U/ml) placebo and baseline Peak P-III-P (U/ml) post-GH IGF1 concentrations in elite athletes (15,16). An Australian study of 699 males and 404 female elite athletes found no significant difference in IGF1 concentrations between African, Asian, Oceanian and Caucasian athletes.…”

Section: Peak Igf1mentioning

confidence: 99%

The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes

Holt

Erotokritou‐Mulligan

McHugh

et al. 2010

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Context: The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH. As previous studies involved predominantly white European athletes, it is important to assess whether the response of these markers to recombinant human GH (rhGH) differs with ethnicity. Objective: To examine the response of serum IGF1 and P-III-P and GH-2000 score to rhGH in non-Caucasian amateur athletes. Design: Double-blind placebo-controlled rhGH administration study. Setting: Wellcome Trust Clinical Research Facility, Southampton General Hospital. Subjects: The study included 31 male and 14 female amateur athletes of different ethnicities. Intervention: The subjects were assigned to treatment with placebo or 0.1 IU/kg per day (low dose) or 0.2 IU/kg per day (high dose) rhGH for 28 days. Blood was collected weekly during treatment and on days 35, 42 and 84 during the washout period. Serum IGF1 and P-III-P were measured, and GH-2000 score was calculated. Results: IGF1, P-III-P and GH-2000 score rose in response to both low-and high-dose GH in both men and women. When compared with the Caucasian volunteers of the previous GH-2000 study, mean baseline and placebo-treated P-III-P and GH-2000 score were lower in GH-2004 men and women. Post-GH, however, peak IGF1 or P-III-P did not differ between studies but the peak GH-2000 score was lower in GH-2004 men. There was no difference between studies in the maximal change in IGF1, P-III-P and GH-2000 score in response to GH in either gender. Conclusions: These data do not support a significant ethnic effect on the peak or maximal response to rhGH.

show abstract

“…4 The GH-2000 detection method provides high sensitivity and specificity 4 and has been validated in an independent GH administration study. 5 In addition, ethnicity 6 and sporting injuries 7 do not affect the reliability of the test. A limitation of all anti-doping tests based on measurements made at a single point in time is that training intensity and volume vary considerably during the season, and these may affect the values on which these tests are based.…”

Section: Introductionmentioning

confidence: 99%

The use of growth hormone (GH)‐dependent markers in the detection of GH abuse in sport: Physiological intra‐individual variation of IGF‐I, type 3 pro‐collagen (P‐III‐P) and the GH‐2000 detection score

Erotokritou‐Mulligan

Bassett

Cowan

et al. 2010

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

Summary Background Growth Hormone is abused by athletes for its lipolytic and anabolic properties. Its use is prohibited by the World Anti‐Doping Agency. The GH‐2000 project developed a methodology to detect its abuse using the concentrations of two GH‐dependent biomarkers, IGF‐I and type 3 procollagen (P‐III‐P). The sensitivity of this method may be improved by considering intra‐individual variability. Aim The aim of this study was to examine the intra‐individual variability of IGF‐I, P‐III‐P and the GH‐2000 score. Subjects and methods IGF‐I, P‐III‐P and GH‐2000 score were evaluated in four longitudinal studies involving 303 elite and 78 amateur athletes. Samples were collected over a period of up to 12 months from a total of 238 men and 143 women aged between 17 and 53 years (mean 24·2). Results The four studies showed good agreement with no apparent difference in within‐individual variation between amateur and elite athletes. The intra‐individual variability for IGF‐I ranged between 14–16% while the variability for P‐III‐P was 7–18%. No athlete tested positive for growth hormone during any of the studies. The overall mean intra‐individual variability of the GH‐2000 score was less than 0·6 units in all studies. Conclusions The high stability of marker levels suggests that concentrations are largely genetically determined. Adopting a test based on the concept of an athlete’s ‘passport’ or ‘profiling’ would take advantage of this and most likely increase the sensitivity of the test. These data also provide strong evidence that a positive test result for GH abuse would not occur as a result of chance variability.

show abstract

Influence of ethnicity on IGF‐I and procollagen III peptide (P‐III‐P) in elite athletes and its effect on the ability to detect GH abuse

Abstract: The GH-2000 detection method based on IGF-I and P-III-P would be valid in all ethnic groups.

Cited by 45 publications

References 14 publications

N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone

N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone

The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes

The use of growth hormone (GH)‐dependent markers in the detection of GH abuse in sport: Physiological intra‐individual variation of IGF‐I, type 3 pro‐collagen (P‐III‐P) and the GH‐2000 detection score

Contact Info

Product

Resources

About